Moderna receives positive opinion from the EMA for Spikevax

Published: 15-Sep-2023
Distribution Regulatory

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation

Moderna has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation for Spikevax.

Spikevax is its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.

Following the CHMP's positive opinion, the European Commission will make an authorisation decision on the use of Moderna's updated COVID-19 vaccine for autumn/winter 2023. 

Our updated COVID-19 vaccine generates a strong human immune response against circulating variants

- Stéphane Bancel, CEO of Moderna

"The CHMP's positive recommendation for our updated COVID-19 vaccine is a key milestone given we see increasing transmission of SARS-CoV-2 across Europe. Our updated COVID-19 vaccine generates a strong human immune response against circulating variants, including BA.2.86, EG.5, and FL.1.5.1, and will be a critical tool for protection," said Stéphane Bancel, CEO of Moderna.

"We are working with governments across Europe to include our updated COVID-19 vaccine in national vaccination programmes, to ensure a diversified portfolio that provides vaccine choice and access to single dose vial formats, which can limit waste," continued Bancel. 

Moderna has generated clinical data of its monovalent XBB.1.5 vaccine candidate showing an immune response against XBB sublineages XBB.1.5, XBB.1.16, and XBB.2.3.2, in addition to BA.2.86, EG.5 and FL.1.5.1 variants.

Like this story? Subscribe to Manufacturing Chemist magazine for the latest news, updates and expert-written articles from the global pharmaceutical and biopharma sectors. For more information click here.

Public health authorities are vigilantly monitoring the BA.2.86 variant, a highly mutated strain of COVID-19 with over 30 mutations as compared to prior Omicron strains, with some governments accelerating COVID-19 vaccination campaigns due to its potential to break through protective immunity generated from previous COVID-19 vaccination or infection. 

The most common solicited local adverse event for Moderna's updated COVID-19 vaccine was injection site pain. The most common solicited systemic adverse events include fatigue, headache, myalgia, arthralgia, and chills. Moderna's updated COVID-19 vaccine's safety prole is consistent with previous Spikevax formulations. 

Moderna has received authorisations for its updated COVID-19 vaccine in the US, Canada, Japan, and Taiwan to date and has submitted regulatory applications worldwide.

  • Companies:
  • EMA European Medicines Agency
  • Moderna Therapeutics
See more

You may also like

Regulatory

Moderna's updated COVID-19 vaccine gets the green light from the FDA

Read more
This year's version of the KP.2-targeting vaccine will endeavour to curb local COVID-19 outbreaks

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Moderna's updated COVID-19 vaccine gets the green light from the FDA

This year's version of the KP.2-targeting vaccine will endeavour to curb local COVID-19 outbreaks
Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Regulatory

Moderna senior executive to speak at the ISPE conference

As Chief Technical Operations and Quality Officer, Andres is responsible for the supply of products required for the company’s preclinical and clinical development programmes
Regulatory

European Commission purchases additional Moderna vaccine doses

Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to be delivered in 2022
Regulatory

MHRA approves Moderna’s COVID-19 vaccine in the UK

The UK is the fifth jurisdiction to authorise Moderna’s vaccine, following the United States, Canada, Israel and the European Union
Regulatory

European Commission authorises Moderna COVID vaccine

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for vaccine based on the totality of scientific evidence shared by the company
Regulatory

Pharma CEOs pledge to uphold scientific standards for COVID vaccine

The pledge outlines "a united commitment to uphold the integrity of the scientific process"
Subscribe now